Elizabeth Migoya
0000-0002-7635-4417
Publication & Citation Trends
Publications
0 total
A Randomized Open-Label Study of Relugolix Alone or Relugolix Combination Therapy in Premenopausal Women OA
Cited by 8
Semantic Scholar
A Phase I Clinical Trial Evaluating the Safety and Dosing of Relugolix with Novel Hormonal Therapy for the Treatment of Advanced Prostate Cancer OA
Cited by 12
Semantic Scholar
Development of relugolix combination therapy as a medical treatment option for women with uterine fibroids or endometriosis OA
Cited by 15
Semantic Scholar
Population PK and Semimechanistic PK/PD Modeling and Simulation of Relugolix Effects on Testosterone Suppression in Men with Prostate Cancer OA
Cited by 12
Semantic Scholar
Relugolix in combination with abiraterone acetate, apalutamide, or docetaxel in men with advanced prostate cancer (aPC): A phase 1, three-part, open-label, parallel-cohort study.
Cited by 1
Semantic Scholar
SIMULATED LONG-TERM EFFECTS OF RELUGOLIX COMBINATION THERAPY ON BONE MINERAL DENSITY AT THE LUMBAR SPINE AS PREDICTED BY A VALIDATED SEMI-MECHANISTIC EXPOSURE-RESPONSE MODEL
Cited by 4
Semantic Scholar
CHARACTERIZATION OF PITUITARY AND OVARIAN HORMONE CONCENTRATIONS DURING TREATMENT WITH RELUGOLIX COMBINATION THERAPY OA
Cited by 3
Semantic Scholar
Effect of Cefiderocol, a Siderophore Cephalosporin, on QT/QTc Interval in Healthy Adult Subjects. OA
Cited by 21
Semantic Scholar
Research Topics
Pharmaceutical studies and practices
(7)
Diabetes Treatment and Management
(6)
Antifungal resistance and susceptibility
(4)
Estrogen and related hormone effects
(4)
Antibiotics Pharmacokinetics and Efficacy
(4)
Affiliations
University of North Carolina at Chapel Hill
Merck & Co., Inc., Rahway, NJ, USA (United States)
Hochschule Hannover
United States Military Academy
Castle Hill Hospital